Anti-Ganglioside GD2 Reference Antibody (Dinutuximab, RUO)
- Catalog number: BS10602
- Availability: In Stock
$176.00
- Ex Tax: $176.00
Description: Dinutuximab (BS10602) is a research-grade recombinant antibody targeting Ganglioside GD2. Produced in mammalian cells with native-like glycosylation.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Chimeric
Isotype: IgG1-kappa
Species reactivity: General
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1.3mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: GangliosideGD2
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: 14.18,MAb-14.18,MOABCh14.18,CAS:1363687-32-4,DGK07804
Background: Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity.
References:
1. Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer., PMID:34596246
2. GD2 is a Crucial Ganglioside in the Signal Modulation and Application as a Target of Cancer Therapeutics., PMID:39921214
3. Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers., PMID:38593230
4. Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma., PMID:39726234
5. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma., PMID:33479234
6. Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins., PMID:35008849
7. RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype., PMID:32486168
8. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M + diffuse midline gliomas., PMID:29662203
9. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma., PMID:20879881
Note: For research use only. Not suitable for clinical or therapeutic use.
Highlights:
• Research Grade — For PK/PD studies, assay development, and ADA research.
• Native Glycosylation — Mammalian expression ensures native-like patterns.
Host species: Chimeric
Isotype: IgG1-kappa
Species reactivity: General
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1.3mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: GangliosideGD2
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: 14.18,MAb-14.18,MOABCh14.18,CAS:1363687-32-4,DGK07804
Background: Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity.
References:
1. Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer., PMID:34596246
2. GD2 is a Crucial Ganglioside in the Signal Modulation and Application as a Target of Cancer Therapeutics., PMID:39921214
3. Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers., PMID:38593230
4. Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma., PMID:39726234
5. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma., PMID:33479234
6. Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins., PMID:35008849
7. RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype., PMID:32486168
8. Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M + diffuse midline gliomas., PMID:29662203
9. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma., PMID:20879881
Note: For research use only. Not suitable for clinical or therapeutic use.
Images
-
BioactivitySEC-HPLC detection for Research Grade Dinutuximab.
